Pyxis Oncology (NASDAQ:PYXS) Given “Outperform” Rating at Royal Bank of Canada

Royal Bank of Canada reaffirmed their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a report issued on Thursday, Benzinga reports. They currently have a $7.00 price objective on the stock.

PYXS has been the subject of several other reports. HC Wainwright reaffirmed a buy rating and set a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a buy rating and a $10.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Pyxis Oncology currently has an average rating of Buy and an average price target of $9.00.

Pyxis Oncology Trading Up 0.3 %

Shares of NASDAQ:PYXS opened at $3.69 on Thursday. The company has a market cap of $217.30 million, a price-to-earnings ratio of -2.71 and a beta of 1.28. The company has a 50-day moving average price of $3.59 and a 200-day moving average price of $3.97. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.04. As a group, research analysts forecast that Pyxis Oncology will post -1.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Pyxis Oncology

Institutional investors have recently bought and sold shares of the stock. Fullcircle Wealth LLC bought a new position in Pyxis Oncology in the second quarter worth about $40,000. SG Americas Securities LLC purchased a new stake in Pyxis Oncology in the first quarter worth about $59,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology in the second quarter worth about $65,000. Cetera Advisors LLC purchased a new stake in Pyxis Oncology in the first quarter worth about $100,000. Finally, Cable Car Capital LLC purchased a new stake in Pyxis Oncology in the fourth quarter worth about $111,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.